الفهرس 
Title : Predictive Factors for The Response of Thrombopoietin Receptor Agonists (TPO-RA) in Patients with Immune Thrombocytopenia (ITP)
contentOnly 14 pages are availabe for public view
 |  | from | 129 |  |  |
| | | from | 129 | | |
Abstract
Immune thrombocytopenia (ITP) is an autoimmune bleeding disorder characterized by low platelet count (peripheral blood platelet count <100 x109 /L). ITP may be asymptomatic but symptoms will be primarily related to bleeding and thrombocytopenia; however many patients experience fatigue and affection of health related quality of life (HRQoL). First line of treatment includes steroids while rescue therapy includes IVIG and Anti D; yet if patient had no response to first line therapy or else contraindicated second line of treatment is recommended as Thrombopoietin receptor agonists (TPO-RA), rituximab and splenectomy. The aim of this study is to identify predictive factors of response to TPO-RA to avoid unwanted adverse effects and to individualize the treatment. Moreover, assessing HRQoL and burden of fatigue in ITP patients treated with TPO-RA compared to general population.